AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Supernus Pharmaceuticals
Acquired Company
SAGE Therapeutics
RockvilleCambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealthcareHealth CareTherapeuticsDescription
Supernus Pharmaceuticals, Inc. has completed its acquisition of SAGE Therapeutics, Inc. for USD 8.50 per share on July 31, 2025. This acquisition integrates SAGE's central nervous system drug pipeline into Supernus's expanding neuropsychiatry portfolio. The deal aims to enhance Supernus's commercial platform with new products like Zurzuvae.
Fundz sees it the moment Supernus Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired SAGE Therapeutics?
SAGE Therapeutics was acquired by Supernus Pharmaceuticals, based in Rockville. The deal was reported on September 24, 2026. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is publicly traded (SUPN) and operates in Biotechnology.
When did Supernus Pharmaceuticals acquire SAGE Therapeutics?
Supernus Pharmaceuticals's acquisition of SAGE Therapeutics was reported on September 24, 2026. Supernus Pharmaceuticals, Inc. has completed its acquisition of SAGE Therapeutics, Inc. for USD 8.50 per share on July 31, 2025. This acquisition integrates SAGE's central nervous system drug pipeline into Supernus's expanding neuropsychiatry portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does SAGE Therapeutics do?
SAGE Therapeutics, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. Its key product, Zurzuvae, targets postpartum depression. The company was previously independently traded on the Nasdaq. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.